Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $25.3 million.

  • Immunome's Accumulated Expenses fell 392.31% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 392.31%. This contributed to the annual value of $33.2 million for FY2024, which is 31342.06% up from last year.
  • As of Q3 2025, Immunome's Accumulated Expenses stood at $25.3 million, which was down 392.31% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Accumulated Expenses registered a high of $33.2 million during Q4 2024, and its lowest value of $3.3 million during Q1 2023.
  • Over the past 3 years, Immunome's median Accumulated Expenses value was $17.7 million (recorded in 2025), while the average stood at $15.6 million.
  • In the last 5 years, Immunome's Accumulated Expenses soared by 68156.72% in 2024 and then tumbled by 1009.67% in 2025.
  • Over the past 3 years, Immunome's Accumulated Expenses (Quarter) stood at $8.0 million in 2023, then surged by 313.42% to $33.2 million in 2024, then fell by 23.75% to $25.3 million in 2025.
  • Its Accumulated Expenses stands at $25.3 million for Q3 2025, versus $18.2 million for Q2 2025 and $17.7 million for Q1 2025.